| TAH Drug Code | IPROG |
|---|---|
| Indications | Amenorrhoea; Dysfunctional uterine bleeding,Recurrent miscarriage w/ progesterone deficiency, |
| Dosing | Pain and bleeding of habitual abortion: 10-25mg daily, then 10mg twice a week IM.Uterine bleeding in middle age and menopause: 5-10mg daily IM. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity; thrombophloebitis; cerebral apoplexy; severe hepatic impairment; undiagnosed vag bleeding, incomplete abortion, hormone-dependent carcinoma, as a diagnostic test for pregnancy; pregnancy. History or current high risk of arterial disease. |
| Adverse Effects | GI disturbances, appetite/wt change, fluid retention, oedema, acne, skin rash, urticaria, depression, headache, fever, fatigue, breast changes, hirsutism, changes in libido, altered menstrual cycles or irregular menstrual bleeding (rare). Gastrointestinal: Abdominal pain (oral, 10% to 20%; vaginal gel, 5% to 12%; vaginal insert, 12% ), Constipation (vaginal gel, 27%; vaginal insert, 2% to 3% ), Nausea (oral, 8%; vaginal gel, 6% to 22%; vaginal insert; 7% to 8% ) Immunologic: Viral disease (oral, 7% to 12% ) Musculoskeletal: Cramp (vaginal gel, 15% to 26% ) Neurologic: Dizziness (oral, 15% to 24%; vaginal gel, 5% ), Headache (oral, 10% to 31%; vaginal gel, 13% to 19%, vaginal insert, 3% to 4% ), Sleep disorder (vaginal gel, 18% ), Somnolence (vaginal gel, 27% ) Psychiatric: Depression (oral, 19%; vaginal gel, 11% to 19% ), Feeling nervous (vaginal gel, 16% ), Mood swings (oral, 6%; vaginal gel, 22% to 23% ) Reproductive: Breast tenderness (oral, 16% to 27% ), Large breast (vaginal gel, 40% ), Pain, Post-oocyte retrieval (vaginal insert, 25% to 28% ), Pain of breast (oral, 6% to 16%; vaginal gel, 13% ), Perineal pain (vaginal gel, 17% ) Other: Fatigue (oral, 8% to 9%; vaginal gel, 21% to 22%; vaginal insert, 2% to 3% ) |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | OUTRO |
|---|---|
| Indications | Oral: Prevention of endometrial hyperplasia in nonhysterectomized, postmenopausal women who are receiving conjugated estrogen tablets; secondary amenorrhea. |
| Dosing | Oral: 200-300mg devided into 1-2 tims. Vaginal: 100mg two times daily. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to progesterone or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or history of arterial thromboembolic disease (eg, stroke, MI); history of or known or suspected carcinoma of the breast or genital organs; hepatic dysfunction or disease; missed abortion or ectopic pregnancy; diagnostic test for pregnancy; capsules are also contraindicated for use during pregnancy |
| Adverse Effects | Central nervous system: Headache (16% to 31%), dizziness (15% to 24%), depression (19%) Endocrine & metabolic: Breast tenderness (27%), breast pain (6% to 16%) Gastrointestinal: Abdominal pain (10% to 20%), abdominal bloating (8% to 12%) Genitourinary: Urinary problems (11%) Neuromuscular & skeletal: Joint pain (20%), musculoskeletal pain (12%) Miscellaneous: Viral infection (12%) |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |